Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

Merck & Co. & Merck Group

4 shared events · Importance 4 · Last updated Sep 12, 2026

Importance
4
Shared Events
4
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
100
Tech
Merck & Co.: Merck co-developed the vaccine and markets Pembrolizumab, which is combined with intismeran. The trial success strengthens Merck's oncology franchise and provides a growth avenue as Pembrolizumab faces patent expiration later this decade.
Merck Group: Merck co-developed the vaccine and provided Pembrolizumab, which is central to the combination. The success strengthens its oncology franchise and provides a new growth opportunity as Pembrolizumab faces patent expiration later this decade.
Aug 19, 2026 · 126 articles
65
Domestic
Merck & Co.: Manufacturer of the MMR vaccine, stated no scientific benefit to splitting it. Faces potential regulatory and market pressure if separate vaccines are developed, but currently no immediate financial impact.
Merck Group: Manufacturer of MMR vaccine, faces potential demand for separate vaccines, but no evidence supports splitting. May face regulatory and financial hurdles.
Aug 10, 2026 · 266 articles
35
Domestic
Merck & Co.: Merck jumped 9.7% following the positive cancer vaccine data, boosting its outlook.
Merck Group: Jumped 10.3% on vaccine data, positive for its Keytruda franchise.
Aug 19, 2026 · 133 articles
17
Business
Merck & Co.: Merck's Lipfendra, the first FDA-approved PCSK9 pill, competes with Scribe's STX-1150. Scribe's epigenetic approach may differentiate it.
Merck Group: Merck's Lipfendra, the first FDA-approved PCSK9 pill, represents a competitive threat to Scribe's injectable therapy. Merck's innovation underscores the competitive landscape.
Jul 06, 2026 · 25 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Merck & Co. and Merck Group interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.